| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | Entrez:608 MIM:109545 HGNC:HGNC:11913 Ensembl:ENSG00000048462 AllianceGenome:HGNC:11913 | |
| Description | TNF receptor superfamily member 17 | |||||
| GTO ID | GTC3589 |
| Trial ID | NCT06045091 |
| Disease | Plasma Cell Leukemia | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-NK cell |
| Treatment | BCMA CAR-NK cells |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL |
| Year | 2023 |
| Country | China |
| Company sponsor | Hrain Biotechnology Co., Ltd. |
| Other ID(s) | HRAIN01-MM04-POC |
| Cohort 1 | |||||||||||||
|
|||||||||||||